A peptic ulcer is a form of painful sore that develops on the mucosal lining of the stomach, small intestine, or lower esophagus. The global peptic ulcer drugs market is growing due to an increase in the prevalence of H. pylori infection, improved diagnostic techniques, easy availability of treatment medication, preferable use of peptic ulcer medication over surgery, an increase in smocking, and overuse of NSAIDs.
The report titled “Peptic Ulcer Drugs Market: Growth, Future Prospects, and Competitive Analysis, 2017–2025” offers strategic insights into the overall peptic ulcer drugs market, along with the market size and estimates for the duration of 2015–2025. The research study covers an in-depth analysis of market segments based on drug class and different geographical regions.
Geographically, the global peptic ulcer drug market is studied for the following regional markets:
- North America
- Rest of Europe
- Rest of Asia-Pacific
- Latin America
- Rest of Latin America
- Middle East and Africa
- GCC Countries
- South Africa
- Rest of Middle East and Africa
The market size and forecast for these regional and country-level markets are presented in this study for the period 2015–2025. Market growth rates for the forecast period 2017–2025 are also included in this report, considering 2016 as the base year.
Along with quantitative information, qualitative information sets and assessment tools are provided in this study for a better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges, and opportunities assists the readers in understanding the ongoing trends in the global peptic ulcer drugs market. In-depth analysis of pipeline molecules for key products in peptic ulcer treatment and global epidemiology data for peptic ulcer have been included in the report.
Tools such as key player market positioning and an appealing investment proposition provide readers with insights into the competitive scenario of the global peptic ulcer drugs market. This report concludes with a company profiles section that highlights major information about the key players engaged in the global peptic ulcer drugs market. In-depth competitive environment analysis and historical year (2015) market size data are also provided in the report.
Thus, the research study provides a holistic view of the global peptic ulcer drugs market, offering market size and estimates for the period from 2015 to 2025, keeping in mind the above-mentioned factors.
Based on drug class, the global peptic ulcer drug market is segmented as follows:
- Proton Pump Inhibitors (PPIs)
- H2 receptor antagonists
- Gastric Mucosal Protective Drugs
- Prostaglandin Agonists
Peptic ulcers are forms of painful sores that develop on the mucosal lining of the stomach, small intestine, or lower esophagus. Some factors such as an increase in the incidence of H. pylori infections, a change in lifestyles such as stress and diet patterns, an increasing smoking rate, the overuse of NSAIDs such as Naproxen, Ibuprofen, Aspirin, and Ketoprofen, improved diagnostic techniques, and the preferable use of medication over surgery are driving the growth of the peptic ulcer drugs market globally.
For the purpose of the study, the peptic ulcer drugs market is segmented on the basis of drug class, such as antibiotics, proton pump inhibitors (PPIs), H2 receptor antagonists, gastric mucosal protective drugs, antacids, prostaglandin agonists. It is studied that, in the base year 2016, PPIs were a major revenue-generating segment because these drugs are preferably prescribed in the market for the treatment of peptic ulcers caused by H. pylori bacterial infection and NSAIDs. PPIs reduce the amount of acid by blocking the action of the parts of cells that produce acid and prevent further damage.
For the purpose of this study, the global peptic ulcer drugs market is categorized into three segments:
- North America
- Asia Pacific
- Latin America (LATAM)
- Middle East and Africa (MEA)
It is studied that, in the base year 2016, North America dominated the peptic ulcer drugs market in terms of revenue, and it is anticipated that it will show steady growth during the forecast period of 2017–2025. Factors such as a large number of affected people, the higher cost of treatment medication, improved diagnostic techniques, and an increase in funding by government agencies in the healthcare system are driving the growth of the peptic ulcer drugs market in North America.
According to the Centers for Disease Control and Prevention (CDC), peptic ulcer disease is a common illness that affects more than 6 million people in the United States annually. It is observed that currently, Europe is the second largest revenue-generating regional market for peptic ulcer drugs due to the higher number of affected people, improved diagnostic techniques, high healthcare awareness, and overuse of pain medication that are driving market growth in Europe.
The U.K., Germany, and France are major revenue-contributing countries in Europe. It is anticipated that Asia Pacific will show the highest growth rate during the forecast period due to populous countries, developing economic conditions, and improving healthcare infrastructure, which will contribute to market growth in Asia Pacific during the forecast period.